Generics Attract Royalty Funding Options Too
Executive Summary
Generics firms also have more financing options, it seems. Last month, Paul Capital Partners, through its Paul Royalty Fund, agreed to invest $27 million in the development of 16 dermatology products at India's Glenmark Pharmaceuticals. It's not big money, but the deal points to the growing clout of the generic segment of the pharma industry.
You may also be interested in...
No Dilution Necessary: The Promise of Project Financing
Project financing, claim its proponents-in particular Symphony Capital-offers an alternative to highly dilutive equity offerings, preserving the upside from the development of a successful product for the biotech. That's true, though this expensive capital isn't for everyone. Yet as Big Pharma's productivity challenge deepens, project financing is helping to swing the balance of power further towards small companies.
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.